A Study of CNTY-101 in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) - Trial NCT06255028
Access comprehensive clinical trial information for NCT06255028 through Pure Global AI's free database. This Phase 1 trial is sponsored by Century Therapeutics, Inc. and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 26 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Century Therapeutics, Inc.
Timeline & Enrollment
Phase 1
Aug 01, 2024
Aug 01, 2028
Primary Outcome
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs,Percentage of Participants With Dose Limiting Toxicities (DLTs),Recommended Phase 2 Regimen (RP2R) With/Without IL-2
Summary
CALiPSO-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety and efficacy
 of CNTY-101 in participants with moderate to severe systemic lupus erythematosus.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06255028
Non-Device Trial